TA treatment significantly ameliorates CCl4-induced liver fibrosis, which may be attributed to the inhibition of the glycerophospholipid metabolism pathway and the PI3K/Akt/mTOR and NF-κB signaling pathways (Figure 10). This evidence concerns the gene NFKB1 and Hepatic fibrosis.